Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Abeona Therapeutics (ABEO)
NASDAQ:ABEO
ABEO Stock Chart & Stats
Day’s Range― - ―
52-Week Range$3.05 - $9.01
Previous CloseN/A
Volume71.38K
Average Volume (3M)243.95K
Market Cap
$228.66M
Enterprise Value$216.95M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta0.44
Next Earnings
Mar 24, 2025EPS Estimate
-0.35Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.70
Shares Outstanding43,471,030
10 Day Avg. Volume331,082
30 Day Avg. Volume243,951
Standard Deviation0.25
R-Squared0.09
Alpha-0.03
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)65.33
Price to Cash Flow (P/CF)-4.70
P/FCF Ratio0.00
Enterprise Value/Market Cap0.95
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit114.48
Enterprise Value/Ebitda-3.39
Forecast
1Y Price Target
$15.00Price Target Upside170.76% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
---
Abeona Therapeutics News
PremiumCompany Announcements
Abeona Therapeutics Reports Q3 2024 Financial Highlights
---
Bulls Say, Bears Say
Bulls Say
Market PositionThe efficacy and long-term durability of prademagene zamikeracel, along with the high list price of a competing product, should enable Abeona to outcompete Filsuvez in the RDEB population.
Medicare ReimbursementFavorable Medicare reimbursement decisions should streamline logistics for prademagene zamikeracel market uptake post-approval.
Regulatory ApprovalAbeona's Biologics License Application for its lead candidate, prademagene zamikeracel, has been accepted by the FDA for review, with an approval decision date set for April 29, 2025.
Bears Say
Competitive LandscapeThe high list price of a competing product could create challenges for Abeona's market penetration.
Financial PerformanceAny negative changes in reimbursement decisions could affect the financial performance and market uptake of prademagene zamikeracel.
Regulatory ChallengesDelays in the FDA's approval process for prademagene zamikeracel could impact Abeona's market entry timeline.
---
Ownership Overview
5.12% Insiders
5.58% Mutual Funds
46.91% Other Institutional Investors
36.84% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ABEO FAQ
What was Abeona Therapeutics’s price range in the past 12 months?
Abeona Therapeutics lowest stock price was $3.05 and its highest was $9.01 in the past 12 months.
What is Abeona Therapeutics’s market cap?
Abeona Therapeutics’s market cap is $228.66M.
When is Abeona Therapeutics’s upcoming earnings report date?
Abeona Therapeutics’s upcoming earnings report date is Mar 24, 2025 which is in 48 days.
How were Abeona Therapeutics’s earnings last quarter?
Abeona Therapeutics released its earnings results on Nov 14, 2024. The company reported -$0.63 earnings per share for the quarter, missing the consensus estimate of -$0.392 by -$0.238.
Is Abeona Therapeutics overvalued?
According to Wall Street analysts Abeona Therapeutics’s price is currently Undervalued.
Does Abeona Therapeutics pay dividends?
Abeona Therapeutics does not currently pay dividends.
What is Abeona Therapeutics’s EPS estimate?
Abeona Therapeutics’s EPS estimate is -0.35.
How many shares outstanding does Abeona Therapeutics have?
Abeona Therapeutics has 43,471,030 shares outstanding.
What happened to Abeona Therapeutics’s price movement after its last earnings report?
Abeona Therapeutics reported an EPS of -$0.63 in its last earnings report, missing expectations of -$0.392. Following the earnings report the stock price went down -2.459%.
Which hedge fund is a major shareholder of Abeona Therapeutics?
Among the largest hedge funds holding Abeona Therapeutics’s share is Western Standard Llc. It holds Abeona Therapeutics’s shares valued at 11M.
---
Abeona Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$15.00 (170.76% Upside)
$15.00 (170.76% Upside)
Blogger Sentiment
Bullish
ABEO Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 111.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $41.9K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 3.2%
Last 30 Days ▼ 4.5%
Last 30 Days ▼ 4.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
10.50%
12-Months-Change
Fundamentals
Return on Equity
-209.50%
Trailing 12-Months
Asset Growth
82.47%
Trailing 12-Months
Company Description
Abeona Therapeutics
Abeona Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of gene therapy for severe and life threatening rare diseases. It programs include EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and ABO-101 (AAV NAGLU), an AAV based gene therapy for Sanfilippo syndrome type B (MPS IIIB). The company was founded in 1974 and is headquartered in New York, NY.
---
ABEO Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call demonstrated significant progress towards the approval and commercialization of pz-cel, with strategic steps in place for launch and financial stability. However, there remain challenges related to manufacturing capacity and ongoing financial losses.Read More>---
ABEO Stock 12 Month Forecast
Average Price Target
$15.00
▲(170.76% Upside)
Technical Analysis
Bioline RX Ltd Sponsored ADR
―
Sorrento Therapeutics
―
uniQure
―
Brainstorm Cell Therapeutics
―
Adaptimmune Therapeutics
―
Best Analysts Covering ABEO
1 Year
1 Year Success Rate
3/6 ratings generated profit
1 Year Average Return
-9.30%
assigned a buy rating 9 months ago
Copying Kristen Kluska's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of -9.30% per trade.
---